Treatment with agalsidase beta during pregnancy in Fabry disease is a research paper published in Journal of Obstetrics and Gynaecology Research (2010). On theSindex it has a DataRank of 2.1. It has been cited 22 times, with 21 citing works in its 1-hop citation network.
AbstractFabry disease is an X‐linked lysosomal storage disease caused by a deficiency of α‐galactosidase A, which leads to excessive accumulation of glycosphingolipids in most tissues in the body, with life‐threatening clinical consequences in the kidney, heart, and cerebrovascular system. Enzyme replacement therapy using exogenously produced α‐galactosidase has been available for treatment of this multisystem progressive disease since 2001. Two different preparations of enzyme replacement therapy for Fabry disease are available outside of the USA: agalsidase alfa and agalsidase beta. Despite being X‐linked, Fabry disease affects many female patients, and this report presents a successful pregnancy of a female patient receiving agalsidase beta.
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
1.6
From 18 citing papers with measurable signal
Ranked by citation count — the same ordering the engine uses when summing log1p(Cq) over citers.
DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 23% comes from its base citations and 77% from the citation network (18 citing papers contributed measurable signal).
Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.
Click a node to highlight its connections. Use scroll to zoom. Drag to pan.